Glaucoma can be treated with lamps and asarum

Abstract: the researchers believe that Erigeron breviscapus is a Chinese herbal medicine with high safety and no systemic toxic and side effects. It can reduce the resistance index of ophthalmic artery, improve microcirculation, improve the visual field defect of early and middle and late glaucoma and improve visual function. It can be used as a visual nerve protector in the treatment of glaucoma after intraocular pressure control.

Ye Changhua, a doctoral student in ophthalmology of the Second Xiangya Hospital of Central South University, found that Erigeron breviscapus can improve the retinal light sensitivity and partially restore the original visual field defect in glaucoma with controlled intraocular pressure.

researchers believe that Erigeron breviscapus is a Chinese herbal medicine with high safety and no systemic toxic and side effects. It can reduce the resistance index of ophthalmic artery, improve microcirculation, improve the visual field defect of early and middle and late glaucoma and improve visual function. It can be used as an optical neuroprotective agent in the treatment of glaucoma after intraocular pressure control. Pharmacological studies have found that Erigeron breviscapus has the effects of anticoagulation and improving microcirculation. It can significantly reduce the vascular tension of middle cerebral artery and increase blood flow. In order to evaluate the neuroprotective effect of Erigeron breviscapus on glaucoma with controlled intraocular pressure, the researchers used a prospective, randomized, double-blind and placebo-controlled research method, A total of 47 glaucoma patients (56 eyes) with controlled intraocular pressure (24-hour intraocular pressure ≤ 21mmhg, fluctuation ≤ 5mmhg) were randomly divided into Erigeron breviscapus treatment group (26 cases, 34 eyes) and placebo group (21 cases, 22 eyes) The results showed that after 6 months, the average light sensitivity of the treatment group increased by 1.35db and that of the control group decreased by 0.36db (P < 0.01); the visual field improvement rates of the treatment group and the control group were 61.8% and 22.7% respectively After 6 months of treatment, the visual field defect score (VFDs) in the treatment group decreased by 1.59, while that in the control group increased by 0.41 (P 15mmhg, while the patients with mean IOP ≤ 15mmhg in the control group had a higher VFDs net writedown score than those with mean IOP > 15mmhg. There was a significant difference between the two groups (P < 0.05). There was a significant difference in the net write down scores of VFDs between the two groups in the early, middle and late stages (P < 0.05). After 6 months of treatment with Erigeron breviscapus, the ophthalmic artery resistance index decreased by 0.08 (P < 0.01). The

shared:

people who read this article should take care of their eyes and more products below >

Compound Xueshuantong capsule: promoting blood circulation and removing blood stasis, supplementing qi and nourishing yin. It is used to treat retinal vein occlusion with blood stasis and deficiency of Qi and Yin, such as decreased vision or abnormal vision, signs of fundus blood stasis, mental fatigue, dry throat, dry mouth, etc; And stable tired angina pectoris for blood stasis and deficiency of Qi and Yin. Symptoms include chest tightness and pain, palpitation, palpitation, palpitation, shortness of breath, fatigue, upset and dry mouth. Citicoline sodium capsule: used to treat the sequelae of nervous system caused by craniocerebral injury or cerebrovascular accident.

price: ¥ 668

IOP lowering drug. Acetazolamide is suitable for chronic open-angle glaucoma and secondary glaucoma. It is also suitable for the preoperative treatment of acute angle closure glaucoma.

and

price: ¥ 25

and

IOP lowering drugs. Acetazolamide is suitable for chronic open-angle glaucoma and secondary glaucoma. It is also suitable for the preoperative treatment of acute angle closure glaucoma. Price of

and

: ¥ 26

and

nourish the liver and kidney, nourish yin, generate fluid, clear the liver and brighten the eyes. It is used for glaucoma, cataract in the early and middle stages, shyness, photophobia, blurred vision and other diseases caused by Yin deficiency of liver and kidney. Price of

and

: ¥ 25

and

nourish the liver and kidney, nourish yin, generate fluid, clear the liver and brighten the eyes. For shyness, photophobia and blurred vision caused by Yin deficiency of liver and kidney; Glaucoma, early and middle cataract with the above syndrome.

price: ¥ 29

for acute angle closure glaucoma, chronic angle closure glaucoma, open angle glaucoma, secondary glaucoma, etc. This product can be combined with other mydriasis agents β Receptor blockers, carbonic anhydrase inhibitors, sympathetic drugs or hypertonic dehydrating agents are used in the treatment of glaucoma. After ophthalmoscopy, this product can be dripped to shrink the pupil to counteract the effect of ciliary muscle paralysis agent or pupil dilator.

and

price: ¥ 7

and

are used to treat uveitis, keratitis and scleritis, inhibit the formation of corneal neovascularization, treat the inflammatory reaction after intraocular surgery, laser curtain forming or various eye injuries, and inhibit the mydriasis reaction in cataract surgery; Used for analgesia and anti-inflammatory after excimer laser keratectomy; Allergic eye diseases such as spring conjunctivitis and seasonal allergic conjunctivitis, prevent and treat inflammation and macular cystoid edema after cataract and intraocular lens surgery, and promote the formation of filtering blebs after glaucoma filtering surgery.

and

price: ¥ 12

and

are used to treat uveitis, keratitis and scleritis, inhibit the formation of corneal neovascularization, treat the inflammatory reaction after intraocular surgery, laser curtain forming or various eye injuries, and inhibit the mydriasis reaction in cataract surgery; Used for analgesia and anti-inflammatory after excimer laser keratectomy; Allergic eye diseases such as spring conjunctivitis and seasonal allergic conjunctivitis, prevent and treat inflammation and macular cystoid edema after cataract and intraocular lens surgery, and promote the formation of filtering blebs after glaucoma filtering surgery. Price of

and

: ¥ 21

and

are used to treat uveitis, keratitis and scleritis, inhibit the formation of corneal neovascularization, treat the inflammatory reaction after intraocular surgery, laser curtain forming or various eye injuries, and inhibit the mydriasis reaction during cataract surgery; Used for analgesia and anti-inflammatory after excimer laser keratectomy; Allergic eye diseases such as spring conjunctivitis and seasonal allergic conjunctivitis, prevent and treat inflammation and macular cystoid edema after cataract and intraocular lens surgery, and promote the formation of filtering blebs after glaucoma filtering surgery.

price: ¥ 7.5

is used to treat uveitis, keratitis and scleritis and inhibit the formation of corneal neovascularization, increase blood flow. In order to evaluate the neuroprotective effect of Erigeron breviscapus on glaucoma with controlled intraocular pressure, the researchers used a prospective, randomized, double-blind and placebo-controlled research method, A total of 47 glaucoma patients (56 eyes) with controlled intraocular pressure (24-hour intraocular pressure ≤ 21mmhg, fluctuation ≤ 5mmhg) were randomly divided into Erigeron breviscapus treatment group (26 cases, 34 eyes) and placebo group (21 cases, 22 eyes) The results showed that after 6 months, the average light sensitivity of the treatment group increased by 1.35db and that of the control group decreased by 0.36db (P < 0.01); the visual field improvement rates of the treatment group and the control group were 61.8% and 22.7% respectively After 6 months of treatment, the visual field defect score (VFDs) in the treatment group decreased by 1.59, while that in the control group increased by 0.41 (P 15mmhg, while the patients with mean IOP ≤ 15mmhg in the control group had a higher VFDs net writedown score than those with mean IOP > 15mmhg. There was a significant difference between the two groups (P < 0.05). There was significant difference in the net write down score of VFDs between the two groups (P < 0.05). After 6 months of treatment with Erigeron breviscapus, the ophthalmic artery resistance index decreased by 0.08 (P < 0.01).